Monte Rosa Therapeutics Inc (GLUE)vsVertex Pharmaceuticals Inc (VRTX)
GLUE
Monte Rosa Therapeutics Inc
$8.64
-3.03%
HEALTHCARE · Cap: $880.99M
VRTX
Vertex Pharmaceuticals Inc
$515.02
-1.08%
HEALTHCARE · Cap: $137.57B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 18317% more annual revenue ($12.95B vs $70.33M). VRTX leads profitability with a 30.7% profit margin vs -186.2%. VRTX earns a higher WallStSmart Score of 58/100 (C).
GLUE
Hold36
out of 100
Grade: F
VRTX
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for GLUE.
Margin of Safety
+46.6%
Fair Value
$974.60
Current Price
$515.02
$459.58 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 325.8% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 37.8%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -26.4% — below average capital efficiency
Negative free cash flow — burning cash
Expensive relative to growth rate
Premium valuation, high expectations priced in
Earnings declined 39.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : GLUE
The strongest argument for GLUE centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 325.8% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 30.7% and operating margin at 37.8%. Revenue growth of 11.8% demonstrates continued momentum.
Bear Case : GLUE
The primary concerns for GLUE are EPS Growth, Market Cap, Return on Equity.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, EPS Growth.
Key Dynamics to Monitor
GLUE profiles as a hypergrowth stock while VRTX is a mature play — different risk/reward profiles.
GLUE carries more volatility with a beta of 1.38 — expect wider price swings.
GLUE is growing revenue faster at 325.8% — sustainability is the question.
VRTX generates stronger free cash flow (546M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (58/100 vs 36/100), backed by strong 30.7% margins and 11.8% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Monte Rosa Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new precision small molecule drugs that employ the body's natural mechanisms to selectively break down therapeutically relevant proteins. The company is headquartered in Boston, Massachusetts.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?